Twist Bioscience Stock Price, News & Analysis

Twist Bioscience Corporation (NASDAQ: TWST) has launched the AsterExome panel, a tool designed to enhance oncology research through comprehensive whole exome sequencing (WES). This panel covers 620 cancer-associated genes, integrated into the AVATAR sequencing program by Aster Insights. It aims to improve the efficiency and accuracy of cancer research, identifying copy number variations and somatic mutations that standard panels may overlook. The collaboration with Aster Insights brings together extensive clinicogenomic data, accelerating the discovery of personalized therapies. This innovation leverages Twist’s proprietary DNA synthesis technology, positioning the company favorably in the competitive oncology research landscape.

Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with Astellas Pharma Inc. to license a suite of VHH antibody libraries aimed at drug discovery and development. This partnership includes three agreements over five years. Twist will receive an upfront payment, annual maintenance fees, and milestone-related payments, potentially extending to royalties on product sales. The collaboration highlights Twist's capacity to support customer needs in pipeline development through its innovative antibody solutions. Twist's VHH libraries can target a wide range of proteins and are designed for high specificity and binding affinity, which improves therapeutic development for diseases like cancer and autoimmune disorders.

Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist T-cell Receptor (TCR) and chimeric antigen receptor (CAR) Libraries, designed to enhance the development of cell therapies. These libraries allow rapid creation of custom gene fragments, enabling researchers to fine-tune receptors for improved therapeutic outcomes. The libraries consist of up to 10,000 gene fragment combinations, facilitating high-throughput screening and exploration of variable binding regions.

CEO Emily M. Leproust stated that the new offerings will aid in addressing challenges like off-target toxicity. The libraries will be showcased at the AACR Annual Meeting 2023 in Orlando, Florida, with specific poster presentations scheduled throughout the event.

Twist Bioscience Corporation (NASDAQ: TWST) has announced its upcoming financial results for the fiscal 2023 second quarter, which ended on March 31, 2023. The results will be released before the market opens on May 5, 2023. A conference call is scheduled for 8:00 a.m. Eastern Time on the same day, where the company's financial performance and business updates will be discussed.

The press release will be available on the company's website in the Investor Relations section prior to the call. Twist Bioscience specializes in high-quality synthetic DNA manufacturing using a proprietary silicon-based platform, focusing on various applications across healthcare, agriculture, and genomics.

Twist Bioscience Corporation (NASDAQ: TWST) announced the launch of its integrated offering of antibody discovery services, combining its synthetic libraries, AI machine learning, and in vivo immunization through the acquisition of Abveris. This premium service aims to provide optimized, development-ready antibody candidates, enhancing throughput and speed for clients. The initiative is led by Tracey Mullen, newly appointed Senior VP of Biopharma. The offering will be showcased at the Festival of Biologics from March 20-22, 2023. The integrated approach facilitates improved discovery and optimization of diverse antibody formats, promoting success in preclinical development.

Twist Bioscience Corporation (NASDAQ: TWST) announced key presentations by CEO Emily M. Leproust and CFO Jim Thorburn at upcoming investor conferences. They will participate in the Cowen 43rd Annual Healthcare Conference on March 6-7, 2023, with a fireside chat on March 7 at 1:30 p.m. ET. The Barclays Global Healthcare Conference will occur on March 14, 2023, featuring a fireside chat at 2:05 p.m. ET. Both events will be webcasted live and available for replay for 30 days. Twist Bioscience specializes in synthetic DNA manufacturing, with applications across healthcare, agriculture, and more.